Company: HCTI
Filing Date: 2025-11-28
Form Type: S-3
Source: 0001213900-25-115888
Chunk: 26

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-28
Form: S-3
Chunk 26
---
 passu with, those of
Common Stock. Additionally, we may acquire other technologies or finance strategic alliances by issuing our equity or equity-linked securities,
which may result in additional dilution. Any issuances by us of equity securities may be at or below the prevailing market price of our
Common Stock and in any event may have a dilutive impact on your ownership interest, which could cause the market price of our Common
Stock to decline. We may also raise additional funds through the incurrence of debt or the issuance or sale of other securities or instruments
senior to our shares of Common Stock. The holders of any securities or instruments we may issue may have rights superior to the rights
of our holders of our Common Stock. If we experience dilution from issuance of additional securities and we grant superior rights to new
securities over common stockholders, it may negatively impact the trading price of our shares of Common Stock.

For more information about our SEC filings, please
see “Where You Can Find More Information” and “Incorporation by Reference.”

Additional risks not presently known or that we
presently consider to be immaterial could subsequently materially and adversely affect our financial condition, results of operations,
business, and prospects.

<div align='center'>13

WARRANT INDUCEMENT PRIVATE PLACEMENT</div>

On November 20, 2025, we entered into the Securities
Purchase Agreement. Under the Securities Purchase Agreement, the Company agreed to issue 20% original issue discount senior unsecured
convertible promissory notes (“Notes”) in an aggregate original principal amount of up to $15,000,000, which will be convertible
into Common Stock. The closing of the first tranche was consummated on November 20, 2025, and the Company issued the initial Note for
an aggregate original principal amount of $7,500,000 (the “Initial Tranche”). The Note issued in the Initial Tranche was sold
to the Investors for a purchase price of $6,000,000, representing an original issue discount of twenty percent (20%), and matures on November
20, 2026. The second Note will be in aggregate original principal amount of $7,500,000 and will be issued after the satisfaction of certain
conditions precedent, including the registration statement relating to this prospectus being declared effective by the SEC and stockholder
approval of the conversion of the Notes. The Company may request that the Investor purchase up to $15 million of additional Notes, which